Utah Medical Products Adjusts Valuation Amid Mixed Financial Performance and Strong Returns

Utah Medical Products, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation, reflecting a revision in its score. This change is primarily attributed to a shift in its valuation grade, which has transitioned from fair to attractive. Key financial metrics indicate a P/E ratio of 16, alongside a Price to Book Value of 1.66. The company also reports an EV to EBIT of 8.92 and an EV to EBITDA of 7.23, suggesting a competitive positioning within its industry. Notably, Utah Medical Products boasts a high return on capital employed (ROCE) of 35.70% and a return on equity (ROE) of 10.68%, highlighting effective management efficiency. Despite these strengths, the company has faced challenges, including negative financial performance in the quarter ending December 2025 and a decline in operating profit over the past five years. The stock has generated a return of 10.73% over the past year, although profits have seen a decrease of 19.7%. With a significant institutional holding of 79.23%, Utah Medical Products, Inc. remains a noteworthy entity in its field. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.